Association of donor-derived host-reactive cytolytic and helper T cells with outcome following alternative donor T cell-depleted bone marrow transplantation

Bone Marrow Transplantation
C A Keever-TaylorL A Baxter-Lowe

Abstract

Recipients of marrow from alternative donors (unrelated or HLA-mismatched related donors) have a higher incidence of post-transplant complications compared to recipients of marrow from HLA-identical siblings. HLA disparity undetected by routine typing techniques has been suggested as one cause for the increased complications observed. Limiting dilution analysis (LDA) of donor-derived, host-reactive T cell precursor frequency prior to transplant has been proposed as a surrogate indicator of underlying HLA disparity which might be used to predict transplant outcome and aid in donor selection. We compared results of LDA of host-reactive IL-2 producing helper T lymphocytes (HTLp) and/or cytolytic T lymphocytes (CTLp) in 77 alternative marrow donor/recipient pairs with transplant outcome using univariate and multivariate analysis. All donor grafts were depleted ex vivo of mature T cells. Median patient age was 15 years (1-53). Donor selection was based on serologic typing for HLA class I and high resolution oligotyping for HLA-DRB1-DRB5, and HLA-DQB1. HLA-A and HLA-B locus antigens were retrospectively defined by one dimensional isoelectric focusing (IEF). Cox proportional hazards regression models were used to assess the impact of ...Continue Reading

Citations

Apr 9, 2001·Journal of Immunological Methods·C A RussellL L Vindeløv
Sep 10, 2005·Bone Marrow Transplantation·M B A HeemskerkM Oudshoorn
May 29, 2007·Bone Marrow Transplantation·M B A HeemskerkM Oudshoorn
Dec 12, 2001·British Journal of Haematology·J ScopesF M Gibson
Jun 12, 1999·British Journal of Haematology·H E Heslop
Mar 13, 2010·Laboratory Hematology : Official Publication of the International Society for Laboratory Hematology·E RettingerP Lang
Nov 18, 2003·Immunological Reviews·Maria P Hernandez-FuentesRobert I Lechler
Jun 5, 2008·International Journal of Laboratory Hematology·B KircherD Nachbaur
Dec 21, 2007·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·N A MifsudJ McCluskey
Dec 20, 2005·Human Immunology·Martin B A HeemskerkMachteld Oudshoorn
Jan 21, 2012·The Journal of Immunology : Official Journal of the American Association of Immunologists·Monique M JörisFrans H J Claas
May 26, 2018·Bone Marrow Transplantation·Katharina FleischhauerBronwen E Shaw

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.